Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer
Not Applicable
Completed
- Conditions
- Breast cancerCancerMalignant neoplasm of breast
- Registration Number
- ISRCTN10773849
- Lead Sponsor
- The Chinese University of Hong Kong
- Brief Summary
2020 Protocol article in http://www.doi.org/10.1097/MD.0000000000019083 (added 19/08/2022)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
1. Chinese women?with histologically confirmed estrogen receptor-positive, stage I–III, primary invasive breast cancer
2. Treated with definitive surgery and/or chemotherapy and started on tamoxifen (20 mg daily) within the past month
Exclusion Criteria
1. Patients with other primary malignancies within the last 5 years
2. Patients who are pregnant or are planning to become pregnant, lactating
3. Treated with investigational drugs within the 4 weeks prior to enrolment
4. Not able to provide informed consent
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method